Molecular Partners’ Post

Come and see our latest news on #RadioDARPin therapeutics at #SNMMI

Start reading our latest case study - European Biotech Builds a Strategy for a Radioligand Therapy in Metastatic Prostate Cancer: https://lnkd.in/emAJturG 💡 About the case study: Our work strengthened the client’s opinion about the viability of the business case, supporting the asset’s further development in the metastatic prostate cancer space. The client was then able to explore key milestones and dynamics to monitor in the future. #biotech #nuclearmedicine

🐁 Discover how to build the optimal preclinical model for cancer drug discovery in just 30 minutes! We’ll explore CDX vs. PDX, tumor microenvironment, study design, and published data: https://bit.ly/3PVjJAN

FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER https://lnkd.in/gAUhZSwJ Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Survival in Pivotal DeLLphi-301 Study Amgen to Host [...]

Many thanks to Daniel Levine for featuring Nuvalent, Inc. on The Bio Report podcast! I had a great time discussing the impact of kinase inhibitors on the precision oncology landscape, the complex chemical challenges facing next generation kinase inhibitors, and Nuvalent, Inc.'s work towards our goal of solving for these challenges by leveraging physician collaboration and structure-based drug design. #NSCLC #PrecisionOncology #Biotech #DrugDevelopment

Diagnostic Performance of 99mTc-iPSMA SPECT/CT in the Initial Staging of Patients with Unfavorable Intermediate-, High-, and Very High-Risk Prostate Cancer: A Comparative Analysis with 18F-PSMA-1007 PET/CT Interesting study involving the radiopharmaceutical showcased in the NOBLE Trial which aims to bridge the gap between rural and metro prostate cancer outcomes. Head to head comparison of iPSMA SPECT with PSMA PET. Excellent results from our colleagues in Mexico. https://lnkd.in/eAY5cekw SPECT/CT on the left column and corresponding PET/CT image in same patient on the right. #prostatecancer #nuclearmedicine #ruralhealthcare

Discover the groundbreaking potential of HER2-CD3-Fc bispecific antibody-encoding mRNA delivered by lipid nanoparticles in suppressing HER2-positive tumor growth. Our latest publication highlights the robust expression and potent T cell cytotoxicity induced by HER2-CD3-Fc mRNA-LNPs, demonstrating a promising therapeutic approach for treating HER2-positive cancer. Learn more about this innovative therapy by reading our full study here: https://hubs.li/Q02KrwZJ0

Opna Bio's Bernice Matusow, MS, presented research yesterday at the American Association of Cancer Research annual meeting on OPN-6602, an EP300/CBP bromodomain inhibitor, which demonstrated potent anti-tumor activity in preclinical models of multiple myeloma. OPN-6602 significantly reduced tumor growth as a single agent (71% tumor growth inhibition) in the OPM-2 human multiple myeloma cell xenograft model as well as increased anti-tumor activity (>100% TGI) in combination studies. Opna plans to initiate a Phase 1 clinical study with OPN-6602 in multiple myeloma patients later this summer. #AACR#multiplemyeloma#Phase1

LABN Trending News: FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER https://lnkd.in/gsKeN3mU Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Survival in Pivotal DeLLphi-301 Study Amgen to Host [...]

Curious about the impact of high sensitivity and absolute quantification in liquid biopsy analysis? Listen to experts, including Prof. dr. Geert Martens from AZ Delta, as they unravel the significance of these aspects in liquid biopsy with Plasma-SeqSensei. NGS liquid-biopsy technology allows to detect DNA mutations🧬 like ESR1, PIK3CA and AKT1. This contributes to the development of therapeutics that enhance every phase of a patient’s journey and extend lives, especially breast cancer patients🎗. Learn more about Plasma-SeqSensei here: https://lnkd.in/eApzPmmb #SysmexBNL#LiquidBiopsy#PrecisionMedicine#ESR1#Breastcancer